Fentanyl analogs: Structure-activity-relationship study

Current Medicinal Chemistry

Volumn 16, Issue 19, 2009, Pages 2468-2474

  Vuckovic S ^a   Prostran, M ^a   Ivanovic M ^b   Dosen Micovic Lj ^b   Todorovic Z ^a   Nesic Z ^a   Stojanovic R ^a   Divac, N ^a   Mikovic Z ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c University Clinic of Gynaecology and Obstetrics Narodni Front   (Serbia)

Author keywords

Analgesic activity; Analogs; Fentanyl; Neurotoxicity; Structure activity relationship (SAR)

Indexed keywords

3 ALLYLFENTANYL; 3 BENZYLFENTANYL; 3 BUTYL FENTANYL; 3 CARBOMETHOXYFENTANYL; 3 ETHYLFENTANYL; 3 ISOPROPYLFENTANYL; 3 PHENETHYLFENTANYL; 3 PROPYLFENTANYL; 4 METHYLFENTANYL; CARFENTANIL; FENTANYL; FENTANYL DERIVATIVE; MEFENTANYL; MORPHINE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTINOCICEPTION; DRUG POTENCY; DRUG STRUCTURE; ISOMERISM; NEUROTOXICITY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANALGESICS, OPIOID; FENTANYL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349386048     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788682074     Document Type: Review

References (70)

1. Gutstein, H.B.; Akil, H. In Goodman & Gilman's The Pharmacological Basis of Therapeutics; Brunton, L.L.; Lazo, J.S.; Parker, K.L., Eds.; 11th Ed; McGraw-Hill Medical Publishing Division: New York, Chapter 21, 2006; pp. 547-90.
2. Casy, A.F.; R. Parfitt, T.; Opioid Analgesics, Plenum Press: N. Y., USA, 1986; pp. 287-301.
3. Janssen, P.A.J.; Niemegeers, C.J.E.; Dony, J.G.H. The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats. Arzneimittel-Forsch. (Drug Res.), 1963, 13, 502-7.
4. Niemegeers, C.J.; Schellekens, K.H.; Van Bever, W.F.; Janssen, P.A. Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs. Arzneimittelforschung. 1976, 26, 1551-6.
5. The Merck Index, 13th Ed., Merck & Co., Inc., New York, 2002.
6. De Vos, V. Immobilisation of free-ranging wild animals using a new drug. Vet Rec., 1978, 103, 64-8.
7. Gommeren, W.; Leysen, J.E. Binding properties of 3H-lofentanil at the opiate receptor. Arch. Int. Pharmacodyn. Ther., 1982, 258, 171-3.
8. Laduron, P.M.; Poncet, J.; Janssen, P.F. Opiate receptors in brain labeled in vivo with [3H]lofentanil. Neuropharmacology, 1985, 24, 617-20.
9. Cookson, R.F.; Niemegeers, C.J.; Vanden Bussche, G. The development of alfentanil. Br. J. Anaesth., 1983, 55, 147S-55S.
10. Janssens, F.; Torremans, J.; Janssen, P.A. Synthetic 1,4- disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic. J. Med. Chem., 1986, 29, 2290-7.
11. Feldman, P.L.; James, M.K.; Brackeen, M.F.; Bilotta, J.M.; Schuster, S.V.; Lahey, A.P.; Lutz, M.W.; Johnson, M.R.; Leighton, H.J. Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. J. Med. Chem., 1991, 34, 2202-8.
12. Pasternak, G.W. Multiple opiate receptors:dE'ja' vu all over again. Neuropharmacology, 2004, 47, 312-23.
13. Lu, Y.F.; Xu, H.; Liu-Chen, L.Y.; Chen, C.; Partilla, J.S.; Brine, G.A.; Carroll, F.I.; Rice, K.C.; Lai, J.; Porreca, F.; Sadee, W.; Rothman, R.B. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor. Synapse, 1998, 28, 117-24.
14. Williams, M.; Kowaluk, E.A; Arneric, S.P. Emerging molecular approaches to pain therapy. J. Med. Chem., 1999, 42, 1481-500.
15. Subramanian, G.; Paterlini, M.G.; Portoghese, P.S.; Ferguson, D.M. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J. Med. Chem., 2000, 43, 381-91.
16. Husbands, S.M.; Lewis, J.W. Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogs of buprenorphine. J. Med. Chem., 2000, 43, 139-41
17. Janecka, A,; Fichna, J.; Janecki, T. Opioid receptors and their ligands. Curr. Top Med. Chem., 2004, 4, 1-17.
18. Subramaniam, A. Opioid ligands with mixed μ / δ opioid receptor interactions: An emerging approach to novel analgesics. AAPS J., 2006, 8, E118-25.
19. Došen-Mićović, L.; Ivanović, M.; Mićović, V. Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg. Med. Chem., 2006, 14, 2887-95.
20. Lee, Y.S.; Nyberg, J.; Moye, S.; Agnes, R.S.; Davis, P.; Ma, S-w; Lai, J; Porreca, F.; Vardanyana, H.V.J. Understanding the structural requirements of 4-anilidopiperidine analogs for biological activities at μ and δ opioid receptors. Bioorg. Med. Chem. Lett., 2007, 17, 2161-5.
21. Jewett, DM.; Kilbourn, M.R. In vivo evaluation of new carfentanil-based radioligands for the mu opiate receptor. Nucl. Med. Biol., 2004, 31, 321-5.
22. Henriksen, G.; Platzer, S.; Marton, J.; Hauser, A.; Berthele, A.; Schwaiger, M; Marinelli, L.; Lavecchia, A.; Novellino, E.; Wester, H.J. Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents. J. Med. Chem., 2005, 48, 7720-32.
23. Lavecchia, A.; Novellino, E.; Wester, H.J. Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents. J. Med. Chem., 2005, 48, 7720-32.
24. Bencherif, B.; Fuchs, P.N.; Sheth, R.; Dannals, R.F.; Campbell, J.N.; Frost, J.J. Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET). Pain, 2002, 99, 589-98.
25. Hirvonen, J,; Aalto, S.; Hagelberg, N.; Maksimow, A.; Ingman, K.; Oikonen,V.; Virkkala, J.; Någren, K.; Scheinin, H. Measurement of central micro-opioid receptor binding in vivo with PET and [(11)C]carfentanil: A test-retest study in healthy subjects. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 275-86.
26. Lembeck, F.; Donnerer, J. Opioid control of the function of primary afferent substance P fibres. Eur. J. Pharmacol., 1985, 114, 241-6.
27. Wager, T.D.; Scott, D.J.; Zubieta, J.K. Placebo effects on human mu-opioid activity during pain. Proc. Natl. Acad. Sci. U.S.A., 2007, 104,11056-61.
28. Riley, T.N.; Hale, D.B.; Wilson, M.C. 4-Anilidopiperidine analgesics. I. Synthesis and analgesic activity of certain ring-methylated 1-substituted 4-propananilidopiperidines. J. Pharm. Sci., 1973, 62, 983-6.
29. Van Bever, W.F.; Niemegeers, C.J.; Schellekens, K.H.; Janssen, P.A. N-4-Substituted 1-(2-arylethyl)-4-piperidinyl-N-phenylpropanamides, a novel series of extremely potent analgesics with unusually high safety margin. Arzneimittelforschung, 1976, 26, 1548-51
30. Riley, T.N.; Bagley, J.R. 4-Anilidopiperidine analgesics. 2. A study of the conformational aspects of the analgesic activity of the 4-anilidopiperidines utilizing isomeric N-substituted 3-(propananilido)nortropane analogs. J. Med. Chem., 1979, 22, 1167-71.
31. Finney, Z.G., Riley, T.N. 4-Anilidopiperidine analgesics. 3. 1-Substituted 4-(propananilido)perhydroazepines as ring-expanded analogs. J. Med. Chem., 1980, 23, 895-9.
32. Casy, A.F.; Huckstep, M.R. Structure-activity studies of fentanyl. J. Pharm. Pharmacol., 1988, 40, 605-8.
33. Colapret, J.A., Diamantidis, G.; Spencer, H.K.; Spaulding, T.C.; Rudo, F.G. Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines. J. Med. Chem., 1989, 32, 968-74.
34. Kudzma, L.V.; Severnak, S.A.; Benvenga, M.J.; Ezell, E.F.; Ossipov, M.H.; Knight, V.V,; Rudo, F.G.; Spencer, H.K.; Spaulding, T.C. 4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents. J. Med. Chem., 1989, 32, 2534- 2.
35. Bagley, J.R.; Kudzma, L.V.; Lalinde, N.L.; Colapret, J.A.; Huang, B.S.; Lin, B.S.; Jerussi, T.P.; Benvenga, M.J.; Doorley, B.M.; Ossipov, M.H.; Spaulding, T.C.; Spencer, H.K.; Rudo, F.G.; Wynn, R.L. Evolution of the 4-anilidopiperidine class of opioid analgesics. Med. Res. Rev., 1991, 11, 403-36.
36. Lalinde, N.; Moliterni, J.; Wright, D.; Spencer, H.K.; Ossipov, M.H.; Spaulding, T.C.; Rudo, F.G. Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics. J. Med. Chem., 1990, 33, 2876-82.
37. Liama, E.F.; del Campo, C.; Capo, M. New heteroaryl derivatives of fentanyl. J. Pharm. Pharmacol., 1991, 43, 68-9
38. Bagley, J.R.; Wynn, R.L.; Rudo, F.G.; Doorley, B.M.; Spencer, H.K.; Spaulding, T. New 4-(heteroanilido)piperidines, structurally related to the pure opioid agonist fentanyl, with agonist and/or antagonist properties. J. Med. Chem., 1989, 32, 663-71.
39. Mićović, I.V.; Roglić, G.M.; Ivanović, M.D.; Došen-Mićović, Lj.; Kiricojević, V.D.; Popović, J.B. The synthesis of lactame analogs of fentanyl. J. Chem. Soc. Perkin. Trans., 1996, 1, 2041.
40. Mićović, I.V.; Ivanović, M.D.; Vučković, S.; Jovanović-Mićić, D.; Beleslin, D.; Došen-Mićović, Lj.; Kiricojević, V.D. 3-Carbomethoxy fentanyl: Synthesis, pharmacology and conformational analysis. Heterocycl. Commun., 1998, 4, 171-9.
41. Mićović, I.V.; Ivanović, M.D.; Vučkovi,́ S.M.; Prostran, M.Š.; Došen-Mićović, L.; Kiricojevic, V.D. The synthesis and preliminary pharmacological evaluation of 4-methyl fentanyl. Bioorg. Med. Chem. Lett., 2000, 10, 2011-4.
42. Vučković, S.; Prostran, M.; Ivanović, M.; Ristović, Z.; Stojanović, R. Antinociceptive activity of the novel fentanyl analog isocarfentanil in rats. Jpn. J. Pharmacol., 2000, 84, 188-95.
43. Lelas, S.; Gerak, L.R.; Landers, L.K.; Brandt, M.R.; Bagley, J.R.; Brockunier, L.L.; France, C.P. Pharmacological profile of a deuterium-substituted mirfentanil derivative, OHM10579, in rhesus monkeys. Pharmacol. Biochem. Behav., 1998, 60, 665-75.
44. Ivanović, M.D.; Mićović, I.V.; Vučković, S.; Prostran, M.; Todorović, Z.; Ivanović, R.; Kiricojević, V.D.; Djordjević, J.B.; Dosen-Micović, Lj. The synthesis and pharmacological evaluation of (±)-2,3-seco-fentanyl analogs. J. Serb. Chem. Soc., 2004, 69, 955-68.
45. Ivanović, M.D.; Mićović, I.V.; Vučković, S.; Prostran, M.; Todorović, Z.; Kricojević, V.D.; Djordjević, J.B.; Došen-Mićović, Lj. The synthesis and preliminary pharmacological evaluation of the racemic cis and trans 3-alkyl fentanyl analogs. J. Serb. Chem. Soc., 2004, 69, 511-26
46. Dong, N.; Lu, W.C.; Chen, N.Y.; Zhu, Y.C.; Chen, K.X.Using support vector classification for SAR of fentanyl derivatives. Acta Pharmacol. Sin., 2005, 26, 107-12.
47. Goicoechea, C.; SÃnchez, E.; Cano, C.; Jagerovic, N.; MartÃn, M.I. Analgesic activity and pharmacological characterization of N- [1-phenylpyrazol]-3-yl-N-1-(2-phenethyl)-4-piperidylpropenamide, a new opioid agonist acting peripherally. Eur. J. Pharmacol., 2008, 24, 595, 22-9.
48. Van Bever, W.F.; Niemegeers, C.J.; Janssen, P.A. Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. J. Med. Chem., 1974, 17, 1047-51.
49. Casy, A.F.; Ogungbamila, F.O. 3-Allyl analogs of fentanyl. J. Pharm. Pharmacol., 1982, 34, 210.
50. Vučković, S.; Prostran, M.; Todorović, Z.; Grbović, L.; Ivanović, M.; Stojanović, R.; Matić, I. Analgesic activity of 3-alkyl fentanyl analogs in rats: structure-activity study. Fundam. Clin. Pharmacol., 1999, 13, 212.
51. Band, L.; Xu, H.; Bykov, V.; Greig, N.; Kim, C.H.; Newman, A.; Jacobson, A.E.; Rice, K.C.; Rothman, R.B. The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: Evidence for a novel mechanism of action. Life Sci., 1990, 47, 2231-40.
52. Xu, H.; Kim, C-H.; Zhu, Y.C.; Weber, R.J.; Jacobson, A.E.; Rice, K.C.; Rothman, R.B. (+)-cis-3-Methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: Evidence for pseudoallosteric modulation. Neuropharmacology, 1991, 3, 455-62.
53. Ni, Q.; Xu, H.; Partilla, J.S.; Stark, P.A.; Carroll, F.I.; Brine, G.A.; Rothman, R.B. Stereochemical requirements for pseudoirreversible inhibition of opioid mu receptor binding by the 3-methylfentanyl congeners, RTI-46144 and its enantiomers: Evidence for different binding domains. Synapse, 1993, 15, 296-306.
54. Cowan, A.; Lewis, J.W.; Macfarlane, I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol., 1977, 60, 537-45.
55. Sarton, E.; Teppema, L.; Dahan, A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/ antagonist buprenorphine. Adv. Exp. Med. Biol., 2008, 605, 486-91.
56. Scholz, J., Steinfath, M.; Schulz, M. Clinical pharmacokineticsof alfentanil, fentanyl and sufentanil. An update. Clin Pharmacokinet., 1996, 31, 275-92.
57. Van Daele, P.G.; De Bruyn, M.F.; Boey, J.M.; Sanczuk, S.; Agten, J.T.; Janssen, P.A. Synthetic analgesics: N-(1-2-arylethyl-4-substituted 4-piperidinyl) N-arylalkanamides. Arzneimittelforschung, 1976, 26, 1521-31.
58. Ivanović, M.; Vučković, S.; Ristović, Z.; Mićović, I.; Beleslin, D. Behavioural effects of fentanyl in rats. Yugoslav. Physiol. Pharmacol. Acta, 1995, 31, 195-9.
59. Vučković, S.; Ivanović, M.; Prostran, M.; Todorović, Z.; Ristović, Z.; Mićović, I.; Beleslin, D. Higher environmental temperature potentiates cataleptic effect of fentanyl in rats. Jpn. J. Pharmacol., 1998, 78, 523-7.
60. Vučković, S.; Jovanović-Mićić, D.; Ivanović, M.; Mićović, I.; Beleslin, D. Neurotoxic effects of 3-alkyl fentanyl analogues. VI World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, Argentina, Acta Physiol. Pharmacol. Ther. Latinoam., 1996, 46, 169.
61. Vučković, S.; Prostran, M.; Todorović, Z.; Stojanović, R.; Nešić, Z.; Ivanović, M.; Matić, I. Neurotoxicity of 3-carbomethoxy fentanyl ("iso-carfentanil") in rats. The 35th Annual meeting of the European Society for Clinical Investigation, Barcelona, Spain. Eur. J. Clin. Invest., 2001, 31, 18.
62. Vučković, S.; Prostran, M.; Ivanović, M.; Todorović, Z.; Stojanović, R.; Nešić, Z.; Milovanović, S. The effects of 3-carbomethoxy fentanyl on body temperature in rats. The 5th Congress of the European Association for Clinical Pharmacology and Therapeutics, Odense, Denmark. Pharmacol. Toxicol., 2001, 89, 98.
63. Prostran, M.; Vučković, S.; Nešić, Z.; Stojanović, R.; Todorović, Z. Analgetic and hypertermic effects of 3-butylfentanyl in rats: Structure-activity relationship. The 15th Congress of the European College of Neuropsychopharmacology, Barcelona, Spain. Eur. Neuropsychopharmacol., 2002, 12, 428.
64. Wirz, S.; Wartenberg, H.C.; Elsen, C.; Wittmann, M.; Diederichs, M.; Nadstawek, J. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: A prospective clinical trial. Clin. J. Pain, 2006, 22, 770-5.
65. Freye, E.; Anderson-Hillemacher, A.; Ritzdorf, I.; Levy, J.V. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract., 2007, 7, 123-9.
66. Narabayashi, M.; Saijo, Y.; Takenoshita, S.; Chida, M.; Shimoyama, N.; Miura, T.; Tani, K.; Nishimura, K.; Onozawa, Y.; Hosokawa, T.; Kamoto, T.; Tsushima, T.; Advisory Committee for Oxycodone Study. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: An open-label trial. Jpn. J. Clin. Oncol., 2008, 38, 296-304.
67. Choi, H.S.; Kim, C.S.; Hwang, C.K.; Song, K.Y.; Wang, W.; Qiu, Y.; Law, P.Y.; Wei, L.N.; Loh, H.H. The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem. Biophys. Res. Commun., 2006, 334, 1132-40.
68. Lenard, N.R.; Daniels, D.J.; Portoghese, P.S.; Roerig, S.C. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur. J. Pharmacol., 2007 566, 75-82.
69. Daniels, D.J.; Lenard, N.R.; Etienne, C.L.; Law, P.Y.; Roerig, S.C.; Portoghese, P.S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 19208-13.
70. Petrov, R.R.; Vardanyan, R.S.; Lee, Y.S.; Ma, S.W.; Davis, P.; Begay, L.J.; Lai, J.Y.; Porreca, F.; Hruby, V.J. Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogs for opioid activity. Bioorg. Med. Chem. Lett., 2006, 16, 4946-50.